Catalyst Calendar
Scope

Wed, Jun 17, 2026

1 updates
CNTB
9:00 AM

Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet with cash runway into 2H 2027 – SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma

Enrollment • Phase 2Topline data expected early September 2026 Tue, Sep 1, 2026connectbiopharm.com

Tue, May 12, 2026

2 updates
CNTB
9:00 AM

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis – – Expect to report topline data from both Phase 2 Seabreeze STAT studies mid-2026 – – $20.2 million private placement financing

Presentation / Abstract • Phase 3Presentation Tue, Mar 31, 2026connectbiopharm.com

Thu, Apr 23, 2026

1 updates